Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension - Nature
- ️O'Rahilly, S.
- ️Thu Dec 23 1999
Day,C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med. 16, 179–192 (1999).
Spiegelman,B. M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514 (1998).
Hattersley,A. T. Maturity onset diabetes of the young; clinical heterogeneity explained by genetic heterogeneity. Diabetic Med. 15, 15–24 (1998).
Flier,J. S. Syndromes of insulin resistance—from patient to gene and back again. Diabetes 41, 1207–1219 (1992).
Krook,A. et al. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 43, 357–368 (1994).
Whitehead,J. P. et al. Molecular scanning of the insulin receptor substrate 1 gene in subjects with severe insulin resistance. Diabetes 47, 837–839 (1998).
Tontonoz,P., Hu,E. & Spiegelman,B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).
Lehmann,J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).
Willson,T. M. et al. The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665–668 (1996).
Matthews,D. R. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).
Danielian,P. S., White,R., Lees,J. A. & Parker,M. G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11, 1025–1033 (1992).
Chakravarti,D. et al. Role of CBP/P300 in nuclear receptor signalling. Nature 383, 99–103 (1996).
Di Renzo,J. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol. Cell. Biol. 17, 2166–2176 (1997).
Mukherjee,R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407–410 (1997).
Collingwood,T. N., Adams,M., Tone,Y. & Chatterjee,V. K. K. Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone β receptors in thyroid hormone resistance syndrome. Mol. Endocrinol. 8, 1262–1277 (1994).
Desbois,C. et al. A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell 67, 731–740 (1991).
Nolte,R. T. et al. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137–143 (1998).
Ristow,M. et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl. J. Med. 339, 953–959 (1998).
Adams,M. et al. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128–5132 (1997).
Beamer,B. A. et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47, 1806–1808 (1998).
Deeb,S. S. et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet. 20, 284–287 (1998).
Sarraf,P. et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell 3, 799–804 (1999).
Libby,P. et al. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546–551 (1999).
Iijima,K. et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Comm. 247, 353–356 (1998).
Ogihara,T., Rakugi,H., Ikegama,H. et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hyperten. 8, 316–320 (1995).
Nakamura,Y. et al. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol. 123, 675–682 (1998).
Satoh,H. et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function. Biochem. Biophys. Res. Comm. 254, 757–763 (1999).
Doi,K. et al. PPARγ modulates endothelial function: effects of thiazolidinediones on endothelial cell growth and secretion of endothelin (ET) and C-type natriuretic peptide (CNP). Circulation 98, 192 (1998).
Young,P. W. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 284, 751–759 (1998).
Forman,B. M. et al. 15-Dexoy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).